PDCD1 and neoplasm: Tumor-specific major histocompatibility complex (MHC) class II (tsMHC-II) may increase tumor cell recognition by immune cells18 and predict the response to anti-PD-1/anti-PD-L1 therapy in melanoma and lung cancer19,20.